Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer

Basit Öğe Kaydı
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorOztekin, Esen
dc.contributor.authorAkdeniz, Nadiye
dc.contributor.authorMorkuzu, Suat
dc.contributor.authorYerlikaya, Halts
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorKaplan, Muhammed Ali
dc.date.accessioned2024-04-24T17:37:50Z
dc.date.available2024-04-24T17:37:50Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: To compare anti-EGFR and anti-VEGF agents in patients with K-RAS wild-type metastatic colorectal cancer (mCRC) with regards to tumor location. Methods: 450 patients diagnosed with mCRC, who applied to our center were included in this retrospective study. Of 450 patients, 303 underwent K-RAS mutation tests, assessed as having right-sided or left-sided mCRC and grouped according to localization of right and left colon. Sixty-five patients with K-RAS wild-type mCRC, who were treated with first-line anti-EGFR or anti-VEGF containing combination therapies of fluorouracil with leucovorin and either irinotecan or oxaliplatin were compared. Results: 393 (87%) out of 450 mCRC patients had left-sided colon cancers, and 57(13%) had right-side colon cancers. K-RAS analysis was performed in 303 of 450 patients with mCRC, 186 (61.4%) patients had K-RAS wild-type and 117 (38.6%) had K-RAS mutant. Median survival for right-sided cancers was 23.3 months and 29.4 months for left-sided cancers (p=0.309). Median progression-free survival (PFS) was 10.4 months (95% CI 7.3-13.4) in the anti-EGFR containing regimens group and 9.7 months (8.2-11.1) in the anti-VEGF containing regimens group (p=0.037); however, median overall survival (OS) was 18.4 months (95% CI 11.7-25.1) in the anti-EGFR containing regimens group and 19.3 months (95% CI 15.7-22.9) in the anti-VEGF containing regimens group (p=0.635). Conclusion: Addition of anti-EGFR in left sided K-RAS wild-type mCRC regarding PFS was beneficial, however there was no difference in terms of OS.en_US
dc.identifier.endpage1506en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue4en_US
dc.identifier.pmid31646798
dc.identifier.scopus2-s2.0-85071679567
dc.identifier.scopusqualityQ3
dc.identifier.startpage1501en_US
dc.identifier.urihttps://hdl.handle.net/11468/21210
dc.identifier.volume24en_US
dc.identifier.wosWOS:000481595900025
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal of Buon
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectColorectal Canceren_US
dc.subjectTumor Locationen_US
dc.subjectK-Ras Wild Typeen_US
dc.subjectAnti-Egfr Therapyen_US
dc.titlePrognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal canceren_US
dc.titlePrognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu